Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease

Table 1 Characteristics of Lipid-lowering drug target genes

Drug class	Related Drugs	Drug targets	Primary pharmacological action	Target genes	Gene region (GRCh3.p13 by NCBI Gene)
Key regulator	RGX-501^a	LDL Receptor	Reduced LDL-C	LDLR	chr19: 11200139–11244496
HMG-CoA reductase inhibitors	Lovastatin Simvastatin Atorvastatin Rosuvastatin Pravastatin Fluvastatin	HMG-CoA reductase		HMGCR	chr5: 74632993–74657941
Cholesterol absorption inhibitors	Ezetimibe	Niemann-Pick C1-like protein 1		NPC1L1	chr7: 44552134–4458092
Proprotein convertase subtilisin/kexin type 9 inhibitors	Alirocumab Evolocumab	Proprotein convertase subtilisin/kexin type 9		PCSK9	chr1: 55505221–55530525
Antisense oligonucleotide targeting ApoB-100 mRNA	Mipomersen	Apolipoprotein B-100		APOB	chr2: 21224301–21266945
Bile acid sequestrants	Colesevelam Colestipol Cholestyramine	ATP Binding Cassette Subfamily G Member 5/ATP Binding Cassette Subfamily G Member 8		ABCG5/ ABCG8^b	chr2: 44039611–44065978/44066110–44110127
Key regulator		Lipoprotein Lipasea	Reduced TG	LPL	chr8: 19796764–19824770
peroxisome proliferator receptor alpha activators	Fenofibrate Gemfibrozil Bezafibrate Clofibrate	Peroxisome proliferator-activated receptor-a		PPARA	chr22:46546429–46639653
Angiopoietin-like 3 Inhibitor	Evinacumab	Angiopoietin-related protein 3		ANGPTL3	chr1: 63063191–63071984
Antisense oligonucleotide targeting ApoC-III mRNA	Volanesorsen	Apolipoprotein C-III		APOC3	chr11: 116700623–116703788

Abbreviation: chr chromosome, mRNA messenger ribonucleic acid, LDL-C low-density lipoprotein cholesterol, TG triglyceride
^aRGX-501 is not yet approved for marketing and is being studied for the treatment of homozygous familial hypercholesterolemia
^bDrug targets of bile acid sequestrants were not specified in the DrugBank. They were identified from a previous study [20]

ISSN: 1476-511X